CTRC Core

总结/摘要 临床和转化研究中心（CTRC） 临床和转化研究核心（CTRC）为神经退行性疾病提供基础设施 (NDD)神经退行性和转化神经科学中心（CNTN）的临床研究。在 第一阶段，核心招募，特征，并保留了一个临床队列，包括超过190个“深度”， 在五个诊断组中的“表型”研究参与者：轻度认知障碍（MCI），轻度 阿尔茨海默病（AD）、无认知障碍的帕金森病（PD）（PD-NC）、轻度认知障碍的PD 认知障碍（PD-MCI）和认知正常对照（CNC）。该队列的数据直接支持 第一阶段的5个项目的研究目标，以及其他几个合作。在第二阶段， 这项研究长达十年。与第一阶段一样，CTRC将为每个项目负责人提供业务和 法规支持、项目管理和研究指导，这将有助于推动他们实现目标 独立融资。2期临床核心的显著增强包括关注以下方面的作用： NDD中的神经炎症。CTRC对神经炎症的多模式方法（包括神经成像， 基于血液的生物标志物，遗传学和临床评估）代表了第一个全面的 在NDD领域的数据库。除了维持临床核心外，CTRC还将专注于增加 传统上代表性不足的患者群体的参与率。将通过以下方式促进参与： 扩大我们的教育和推广计划。该计划在第一阶段实施， 通过社区咨询委员会（CAB）的投入，包括一个创新的教育和推广网站 （Healthybrains.org）.最后，该核心还将在南内华达州建立第一个生物银行。 内华达-拉斯维加斯（UNLV）在Jefferson Kinney博士的指导下。这个新的资源将存储，分析， 并提供非临床和临床生物样本评价方面的专业知识。除了支持 在目前提出的项目中，一些额外的COBRE和非COBRE合作者将访问此 宝贵的资源。CTRC具有嵌入式的形成性和总结性评估， 成功实现其具体目标。

SUMMARY/ABSTRACT Clinical and Translational Research Core (CTRC) The Clinical and Translational Research Core (CTRC) provides the infrastructure for neurodegenerative disease (NDD) clinical research within the Center for Neurodegenerative and Translational Neuroscience (CNTN). In Phase 1, the Core recruited, characterized, and retained a clinical cohort consisting of more than 190 “deeply phenoyped” research participants across five diagnostic groups: mild cognitive impairment (MCI), mild Alzheimer’s disease (AD), Parkinson’s disease (PD) with no cognitive impairment (PD-NC), PD with mild cognitive impairment (PD-MCI), and cognitively normal controls (CNC). Data from this cohort directly supported the research goals of 5 projects in Phase 1, as well several other collaborations. In Phase 2, the core will extend the study up to ten years. As in Phase 1, the CTRC will provide each project leader with operational and regulatory support, project management, and research instruction that will help advance them toward the goal of independent funding. A notable enhancement of the Clinical Core in Phase 2 includes a focus on the role of neuroinflammation in NDD. The CTRC’s multimodal approach to neuroinflammation (including neuroimaging, blood-based biomarkers, genetics, and clinical assessments) represents one of the first comprehensive databases in the field of NDD. In addition to sustaining the clinical core, the CTRC will focus on increasing participation rates of traditionally underrepresented patient populations. Participation will be facilitated through expansion of our education and outreach program. This program, which was implemented in Phase 1, is guided by input from a Community Advisory Board (CAB) and includes an innovative education and outreach website (Healthybrains.org). Finally, the core will also establish the first biobank in Southern Nevada at the University of Nevada-Las Vegas (UNLV) under the direction of Dr. Jefferson Kinney. This new resource will store, analyze, and provide expertise in the evaluation of non-clinical and clinical biospecimens. In addition to supporting the currently proposed projects, a number of additional COBRE and non-COBRE collaborators will access this valuable resource. The CTRC has formative and summative assessments imbedded within in that will insure success in achieving its specific aims.